HUP0400323A2 - Tirozin-kináz inhibitorok és a vegyületeket tartalmazó gyógyszerkészítmények - Google Patents

Tirozin-kináz inhibitorok és a vegyületeket tartalmazó gyógyszerkészítmények

Info

Publication number
HUP0400323A2
HUP0400323A2 HU0400323A HUP0400323A HUP0400323A2 HU P0400323 A2 HUP0400323 A2 HU P0400323A2 HU 0400323 A HU0400323 A HU 0400323A HU P0400323 A HUP0400323 A HU P0400323A HU P0400323 A2 HUP0400323 A2 HU P0400323A2
Authority
HU
Hungary
Prior art keywords
alkyl
heteroaryl
aryl
group
nr60r61
Prior art date
Application number
HU0400323A
Other languages
English (en)
Inventor
Mark D. Wittman
Neelakantan Balasubramanian
Upender Velaparthi
Kurt Zimmermann
Mark G. Saulnier
Peiying Liu
Xiaopeng Sang
David B. Frennesson
Karen M. Stoffan
James G. Tarrant
Original Assignee
Bristol-Myers Squibb Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol-Myers Squibb Company filed Critical Bristol-Myers Squibb Company
Publication of HUP0400323A2 publication Critical patent/HUP0400323A2/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

A találmány általános képletű vegyületekre - amelyek képletében Xnitrogén-, szénatom, alkilcsoport vagy kémiai kötés; Y oxigén- vagykénatom; W nitrogén-, szén-, oxigén- vagy kénatom, azzal amegkötéssel, hogy ha W oxigén- vagy kénatom, akkor R9 nincs jelen; R1.R2, R3, R4, R5, R6, R7, R8 és R9 hidrogén-, halogénatom, alkil-,alkenil-, alkinil-, cikloalkil-, heterocikloalkil-, amino-, OR60,nitro-, hidroxi-, -SR60, -NR60R61, ciano-, -CO2R60, -CONR60R61, -CO2-NR60R61, -NR62CONR60R61, -NR60SO2R61, -SO2NR60R61, -C(NR62)-NR60R61,aril-, heteroaril-, -(CH2)nOR60, -(CH2)nNR60R61, -(CH2)nSR60, -(CH2)n-aril, -(CH2)n-heteroaril, -(CH2)n-heterocikloalkil, -NH-Z-aril és -NH-Z-heteroaril csoport; ahol n értéke 1, 2 vagy 3; és Z adott esetbenszubsztituált alkilén-, alkenilén- vagy alkiniléncsoport, amely adottesetben egy vagy több CO, CNOH, CNOR60, CNNR60, CNNCOR60 és/vagyCNNSO2R60 csoportot tartalmaz; R60, R61 és R62 hidrogénatom, alkil-,alkenil-, alkinil-, cikloalkil-, cikloalkil-alkil-, hidroxi-, alkoxi-,aril-, heteroaril-, heteroaril-alkil-csoport, -alkil-R25 csoport; R25hidrogén-, halogénatom, alkenil-, hidroxi-, merkapto-, alkoxi-, alkil-tio-, amino-, alkil-amino-, dialkil-amino-, aril-, heteroaril-,ciano-, szulfinil-, szulfonilcsoport, -NR30COOR31, -NR30C(O)R31, -NR30SO2R31, -C(O)NR30R31, heteroaril vagy heterocikloalkil-csoport;valamint R30, R31 hidrogénatom, alkil-, cikloalkil-, -alkil-R25-csoport - és enantiomereikre, diasztereomereikre, gyógyszerészetilegelfogadható sóikra, hidrátjaikra, prodrugjaikra és szolvátjaikra,ezeket tartalmazó, tirozin-kináz enzimekkel kapcsolatos állapotok, rákés proliferatív betegségek kezelésére használhatógyógyszerkészítményekre vonatkozik.
HU0400323A 2001-03-28 2002-03-26 Tirozin-kináz inhibitorok és a vegyületeket tartalmazó gyógyszerkészítmények HUP0400323A2 (hu)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US27932701P 2001-03-28 2001-03-28
PCT/US2002/009402 WO2002079192A1 (en) 2001-03-28 2002-03-26 Novel tyrosine kinase inhibitors

Publications (1)

Publication Number Publication Date
HUP0400323A2 true HUP0400323A2 (hu) 2005-11-28

Family

ID=23068491

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0400323A HUP0400323A2 (hu) 2001-03-28 2002-03-26 Tirozin-kináz inhibitorok és a vegyületeket tartalmazó gyógyszerkészítmények

Country Status (25)

Country Link
EP (1) EP1381598A4 (hu)
JP (1) JP2004534010A (hu)
KR (1) KR20030083016A (hu)
CN (1) CN1514833A (hu)
AR (1) AR035804A1 (hu)
BG (1) BG108206A (hu)
BR (1) BR0208373A (hu)
CA (1) CA2442428A1 (hu)
CZ (1) CZ20032615A3 (hu)
EE (1) EE200300475A (hu)
GE (1) GEP20053660B (hu)
HR (1) HRP20030844A2 (hu)
HU (1) HUP0400323A2 (hu)
IL (1) IL158041A0 (hu)
IS (1) IS6968A (hu)
MX (1) MXPA03008690A (hu)
NO (1) NO20034308L (hu)
PE (1) PE20021015A1 (hu)
PL (1) PL373300A1 (hu)
RU (1) RU2003131693A (hu)
SK (1) SK12002003A3 (hu)
UY (1) UY27234A1 (hu)
WO (1) WO2002079192A1 (hu)
YU (1) YU84603A (hu)
ZA (1) ZA200307466B (hu)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7081454B2 (en) * 2001-03-28 2006-07-25 Bristol-Myers Squibb Co. Tyrosine kinase inhibitors
MXPA04008408A (es) 2002-03-01 2004-11-29 Squibb Bristol Myers Co Mamiferos no humanos, transgenicos, que expresan receptores de la tirosina cinasa activados constitutivamente.
MXPA04012440A (es) * 2002-06-12 2005-04-28 Abbott Lab Antagonistas de receptor de hormona concentradora de melanina.
AU2003293333A1 (en) * 2002-12-02 2004-06-23 Arqule, Inc. Method of treating cancers
US7189716B2 (en) 2003-01-03 2007-03-13 Bristol-Myers Squibb Company Tyrosine kinase inhibitors
JP2006516626A (ja) * 2003-01-28 2006-07-06 スミスクライン ビーチャム コーポレーション 化学的化合物
US7312215B2 (en) 2003-07-29 2007-12-25 Bristol-Myers Squibb Company Benzimidazole C-2 heterocycles as kinase inhibitors
EP1663204B1 (en) 2003-08-29 2014-05-07 Exelixis, Inc. C-kit modulators and methods of use
US20050075358A1 (en) * 2003-10-06 2005-04-07 Carboni Joan M. Methods for treating IGF1R-inhibitor induced hyperglycemia
DE102004010207A1 (de) * 2004-03-02 2005-09-15 Aventis Pharma S.A. Neue 4-Benzimidazol-2-yl-pyridazin-3-on-Derivate
TW201134828A (en) 2004-04-02 2011-10-16 Osi Pharm Inc 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors
CA2591413A1 (en) * 2004-12-16 2006-06-22 Vertex Pharmaceuticals Incorporated Pyrid-2-ones useful as inhibitors of tec family protein kinases for the treatment of inflammatory, proliferative and immunologically-mediated diseases
WO2006130657A2 (en) 2005-05-31 2006-12-07 Bristol-Myers Squibb Company Stereoselective reduction process for the preparation of pyrrolotriazine compounds
CA2618360C (en) 2005-08-04 2015-06-09 Sirtris Pharmaceuticals, Inc. Benzothiazoles and thiazolopyridines as sirtuin modulators
US8093401B2 (en) 2005-08-04 2012-01-10 Sirtris Pharmaceuticals, Inc. Sirtuin modulating compounds
US8088928B2 (en) 2005-08-04 2012-01-03 Sirtris Pharmaceuticals, Inc. Sirtuin modulating compounds
US7855289B2 (en) 2005-08-04 2010-12-21 Sirtris Pharmaceuticals, Inc. Sirtuin modulating compounds
EP1919905B1 (en) 2005-08-29 2011-02-23 Vertex Pharmaceuticals Incorporated 3,5-disubstituted pyrid-2-ones useful as inhibitors of tec family of non-recptor tyrosine kinases
ATE548363T1 (de) 2005-08-29 2012-03-15 Vertex Pharma 3,5-disubstituierte pyrid-2-one, die sich als inhibitoren der tec-familie von nicht-rezeptor- tyrosinkinasen eignen
EP1919906B1 (en) 2005-08-29 2011-10-12 Vertex Pharmaceuticals Incorporated 3, 5-disubstituted pyrid-2-ones useful as inhibitors of tec family of non-receptor tyrosine kinases
WO2007026720A1 (ja) * 2005-08-31 2007-03-08 Taisho Pharmaceutical Co., Ltd. 縮環ピラゾール誘導体
US8575164B2 (en) 2005-12-19 2013-11-05 OSI Pharmaceuticals, LLC Combination cancer therapy
WO2007145203A1 (ja) * 2006-06-13 2007-12-21 Daiichi Fine Chemical Co., Ltd. 光学活性２－アミノ－１－（４－フルオロフェニル）エタノール
US8063225B2 (en) 2006-08-14 2011-11-22 Chembridge Corporation Tricyclic compound derivatives useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders
WO2008022747A1 (en) * 2006-08-21 2008-02-28 F. Hoffmann-La Roche Ag Tricyclic lactam derivatives, their manufacture and use as pharmaceutical agents
WO2008025526A1 (en) * 2006-08-31 2008-03-06 F. Hoffmann-La Roche Ag Indole derivatives, their manufacture and use as pharmaceutical agents
EP2145021A2 (en) 2007-05-17 2010-01-20 Bristol-Myers Squibb Company Biomarkers and methods for determining sensitivity to insulin growth factor-1 receptor modulators
TW200916472A (en) 2007-06-20 2009-04-16 Sirtris Pharmaceuticals Inc Sirtuin modulating compounds
CA2690064A1 (en) * 2007-06-25 2008-12-31 Guy Georges Benzimidazole amido derivatives as kinase inhibitors
EP2065380A1 (en) * 2007-08-22 2009-06-03 F.Hoffmann-La Roche Ag Pyridoneamide derivatives as focal adhesion kinase (FAK) inhibitors and their use for the treatment of cancer
US7816540B2 (en) * 2007-12-21 2010-10-19 Hoffmann-La Roche Inc. Carboxyl- or hydroxyl-substituted benzimidazole derivatives
MX2010007525A (es) 2008-01-22 2010-08-18 Vernalis R&D Ltd Derivados de indolil-piridona que tienen actividad inhibitoria de la cinasa 1 de punto de control.
JP2011520970A (ja) 2008-05-19 2011-07-21 オーエスアイ・フアーマスーテイカルズ・インコーポレーテツド 置換されたイミダゾピラジン類およびイミダゾトリアジン類
MY160006A (en) 2008-12-19 2017-02-15 Sirtris Pharmaceuticals Inc Thiazolopyridine sirtuin modulating compounds
DE102010001064A1 (de) * 2009-03-18 2010-09-23 Bayer Schering Pharma Aktiengesellschaft Substituierte 2-Acetamido-5-Aryl-1,2,4-triazolone und deren Verwendung
JP2012524119A (ja) 2009-04-20 2012-10-11 オーエスアイ・ファーマシューティカルズ，エルエルシー Ｃ−ピラジン−メチルアミンの調製
US8536180B2 (en) * 2009-05-27 2013-09-17 Abbvie Inc. Pyrimidine inhibitors of kinase activity
EP2494070A2 (en) 2009-10-30 2012-09-05 Bristol-Myers Squibb Company Methods for treating cancer in patients having igf-1r inhibitor resistance
EA022623B1 (ru) * 2010-10-06 2016-02-29 ГЛАКСОСМИТКЛАЙН ЭлЭлСи Производные бензимидазола в качестве ингибиторов pi3-киназ
WO2012061169A1 (en) * 2010-11-01 2012-05-10 Boehringer Ingelheim International Gmbh Benzimidazole inhibitors of leukotriene production
EP2766497A1 (en) 2011-10-13 2014-08-20 Bristol-Myers Squibb Company Methods for selecting and treating cancer in patients with igf-1r/ir inhibitors
EP3010918B1 (en) 2013-06-21 2018-08-15 Zenith Epigenetics Ltd. Novel substituted bicyclic compounds as bromodomain inhibitors
PL3010503T3 (pl) 2013-06-21 2020-08-24 Zenith Epigenetics Ltd. Nowe bicykliczne inhibitory bromodomen
EP3027604B1 (en) 2013-07-31 2019-02-20 Zenith Epigenetics Ltd. Novel quinazolinones as bromodomain inhibitors
CN103936719A (zh) * 2014-05-14 2014-07-23 中国药科大学 苯并咪唑类衍生物制备方法及用途
JP2017525351A (ja) 2014-07-30 2017-09-07 イェダ リサーチ アンド ディベロップメント カンパニー リミテッドＹｅｄａ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｄｅｖｅｌｏｐｍｅｎｔ Ｃｏ．Ｌｔｄ． 多能性幹細胞の培養用培地
EP3227281A4 (en) 2014-12-01 2018-05-30 Zenith Epigenetics Ltd. Substituted pyridinones as bromodomain inhibitors
WO2016092375A1 (en) 2014-12-11 2016-06-16 Zenith Epigenetics Corp. Substituted heterocycles as bromodomain inhibitors
CA2966450A1 (en) 2014-12-17 2016-06-23 Olesya KHARENKO Inhibitors of bromodomains
CA2982664A1 (en) * 2015-04-16 2016-10-20 Merck Patent Gmbh 3-(1h-benzimidazol-2-yl)-1h-pyridin-2-one derivatives
EP3914698A1 (en) 2019-01-23 2021-12-01 Yeda Research and Development Co. Ltd Culture media for pluripotent stem cells
CN117069696B (zh) * 2023-08-17 2024-04-26 中国药科大学 一种双靶点小分子抑制剂及其制备方法和应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6162804A (en) * 1997-09-26 2000-12-19 Merck & Co., Inc. Tyrosine kinase inhibitors
PL206826B1 (pl) * 1999-06-23 2010-09-30 Sanofi Aventis Deutschland Podstawione benzimidazole
US7081454B2 (en) * 2001-03-28 2006-07-25 Bristol-Myers Squibb Co. Tyrosine kinase inhibitors

Also Published As

Publication number Publication date
AR035804A1 (es) 2004-07-14
PE20021015A1 (es) 2002-11-10
CA2442428A1 (en) 2002-10-10
EP1381598A1 (en) 2004-01-21
SK12002003A3 (en) 2004-10-05
IS6968A (is) 2003-09-26
EE200300475A (et) 2004-02-16
KR20030083016A (ko) 2003-10-23
HRP20030844A2 (en) 2005-08-31
NO20034308D0 (no) 2003-09-26
EP1381598A4 (en) 2008-03-19
GEP20053660B (en) 2005-11-10
NO20034308L (no) 2003-11-26
JP2004534010A (ja) 2004-11-11
BG108206A (bg) 2004-11-30
IL158041A0 (en) 2004-03-28
RU2003131693A (ru) 2005-05-10
WO2002079192A1 (en) 2002-10-10
MXPA03008690A (es) 2003-12-12
CN1514833A (zh) 2004-07-21
CZ20032615A3 (en) 2004-03-17
ZA200307466B (en) 2005-01-13
YU84603A (sh) 2006-03-03
UY27234A1 (es) 2002-10-31
PL373300A1 (en) 2005-08-22
BR0208373A (pt) 2005-02-22

Similar Documents

Publication Publication Date Title
HUP0400323A2 (hu) Tirozin-kináz inhibitorok és a vegyületeket tartalmazó gyógyszerkészítmények
CY1107915T1 (el) Τρικυκλικες σπιροπιπεριδινες ή σπιροπυρρολιδινες
HUP0401783A2 (hu) 3,4-Diszubsztituált ciklobutén-1,2-dionok mint CXC-kemokin receptor ligandumok, alkalmazásuk és ezeket tartalmazó gyógyszerkészítmények
CY1108894T1 (el) Νεα παραγωγα βενζιμιδαζολης
DE60226912D1 (de) Chinolin- und Chianzolinderivate zur Behandlung von Tumoren
HUP0402225A2 (hu) Makrolid-vegyületek, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
PE20040155A1 (es) Derivados aminoinazoles, procedimiento de preparacion e intermedios de este procedimiento a titulo de medicamentos y composiciones farmaceuticas que los contienen
HUP0300838A2 (hu) Új heteroarilszármazékok, eljárás az előállításukra és gyógyszerként való alkalmazásuk
HUP0500573A2 (hu) Trifenil-etilén származékok, mint szelektív ösztrogén receptor modulátorok és ezeket tartalmazó gyógyszerkészítmények
HUP0401009A2 (hu) 5-Hidroxitriptamin-6-ligandumokként alkalmazható 1-aril- vagy 1- alkil-szulfonilbenzazol-származékok, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
CY1107677T1 (el) Παραγωγα της 1-[indol-3-yl)carbonyl]piperazine
ATE307810T1 (de) Imidazol-2-carbonsäureamid derivate als raf- kinase-inhibitoren
NO20054361D0 (no) Benzensylfonamidderivater, fremgangsmate for fremstilling og anvendelse derav for behandlig av smerte
AP1816A (en) 3-azabicyclo (3.1.0) hexane derivatives as opioid receptor antagonists.
ATE501128T1 (de) 1,2,3-triazolamidderivate als inhibitoren der cytokinproduktion
HUP0203054A2 (hu) Farnezil protein transzferáz inhibitorok, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
ATE498600T1 (de) Inden derivate als pharmazeutika
HUP0400341A2 (hu) Ciano-szubsztituált dihidropirimidin-vegyületek és alkalmazásuk
ATE482933T1 (de) Sulfopyrrolderivate
NO20034215L (no) Nye amider, fremstilling og terapeutisk anvendelse av modulatorer av CCR-reseptoraktivitet
DE60237512D1 (de) N-(aryl)-2-arylethensulfonamide und ihre therapeutischen anwendungen
ATE315563T1 (de) Piperidinylmorpholinylderivate als modulatoren der aktivität des chemokinrezeptors
HUP0303186A2 (hu) 4-Amino-benzopirán-származékok
HUP0301551A2 (hu) 5-HT3 és idegi nikotinsav receptor antagonista 1-amino-alkil-ciklohexán származékok új alkalmazása
DE60314381D1 (de) Benzylimidazolyl substituierte 2-chinolon und chinazolinon derivate zur verwendung als farnesyl transferase inhibitoren

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees